Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
An update from Nyxoah ( (NYXH) ) is now available.
On May 30, 2025, Nyxoah SA announced that it received a transparency notification from Vestal Point Capital, indicating an acquisition or disposal of voting securities or rights. As of May 21, 2025, Vestal Point Capital holds 1,809,843 voting rights, representing 4.84% of the total voting rights, just below the 5% threshold. This notification highlights a shift in shareholder structure, which could impact Nyxoah’s governance and decision-making processes.
The most recent analyst rating on (NYXH) stock is a Buy with a EUR19.00 price target. To see the full list of analyst forecasts on Nyxoah stock, see the NYXH Stock Forecast page.
More about Nyxoah
Nyxoah SA is a company operating in the medical technology industry, focusing on the development and commercialization of innovative solutions for the treatment of sleep apnea. The company is known for its implantable neurostimulation devices designed to treat Obstructive Sleep Apnea (OSA) by stimulating the hypoglossal nerve to maintain an open airway during sleep.
Average Trading Volume: 87,776
Current Market Cap: €263.1M
For an in-depth examination of NYXH stock, go to TipRanks’ Stock Analysis page.